FindTrial
Sign In

To explore the expression level of orexin-A in OSA and insomnia and its diagnostic and prognostic value

To explore the difference of orexin-A expression in different clinical phenotypes of OSA and its diagnostic and prognostic value

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051968
Enrollment
Unknown
Registered
2021-10-11
Start date
2021-10-10
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea, OSA

Interventions

Experimental group 1:None
Experimental group 2:None
Control group:None

Sponsors

The Second Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 80 years; 2.Meet the diagnostic criteria of ICSD-3 for OSA; 3.Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.History of severe neuropsychiatric disorders; 2.Severe cognitive decline; 3.Substances, drugs (such as alcohol, nicotine, opioids, etc.) abuse or dependence.

Design outcomes

Primary

MeasureTime frame
Orexin;Sleep related parameters;—

Countries

China

Contacts

Public ContactSu Changjun

The Second Affiliated Hospital of Air Force Military Medical University

changjunsu@163.com+86 13991387536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026